Immunocore 2024 Q2 1H Financial Results Earnings

Immunocore presented its 2Q and 1H 2024 financial results and business updates, highlighting progress across oncology, autoimmune, and infectious disease therapeutic areas. The presentation covered KIMMTRAK commercialization growth opportunities, pipeline development, and strategic pillars for advancing immunomodulating medicines.